Science

Biologics reimagined: Synteins™

Biologics have transformed medicine. However, conventional biologics are built only from nature’s molecular toolkit of 20 L-amino acids, creating important limitations that impact their therapeutic potential.

Abiologics is expanding what is possible in protein therapeutics by creating Synteins™ – supranatural, programmable medicines designed from an expanded set of synthetic building blocks. One example is D-amino acids.

At the chemical level, D- and L-amino acids are mirror images of one another. But creating functional D-proteins isn’t as simple as mirroring proteins found in nature. Much like a right-handed glove is shaped for a right hand, a mirror image of an L-protein would not be biologically active against a natural target.

To unlock this new modality, Abiologics developed a novel platform for de novo protein generation, combining generative AI and chemical synthesis to design D-proteins that can engage natural biological targets. And because enzymes, proteases, and immune receptors have evolved to recognize L-proteins, D-proteins can offer properties that are difficult or impossible for conventional biologics to achieve, including protease stability, immune stealth, and enhanced tissue access.

The Abiologics platform: making the ordinary extraordinary.

The Abiologics platform is a fully integrated, digital and automated wet-lab infrastructure that creates supranatural biologics with powerful, desirable pharmacological properties. It is the first to create an experimentally confirmed structure of a de novo AI-designed protein composed entirely of D-amino acids binding to a natural biological target.

Digitally designed

Entering the digital world to design biologics built for purpose

Leveraging artificial intelligence, we can apply the predictable folding rules of natural proteins to create the blueprints for Synteins™ de novo. This enables us to design binders, inhibitors, agonists, and delivery vehicles with novel structures, expanded functions, and advantageous properties such as specificity, immune evasion, protease resistance, and deep-tissue access – and to do so against virtually any therapeutic target. Novel Syntein-drug conjugates, radioligands, and binders all become possible like never before.

Synthetically made

Augmenting nature’s toolkit to develop synthetic biologics

Unlike conventional biologics, which rely on living cells for production, Synteins™ are chemically synthesized. This enables Abiologics to create powerful, AI-designed proteins from an expanded set of synthetic building blocks that are inaccessible to nature. Each experiment feeds a growing proprietary dataset of previously unexplored protein interactions, continuously strengthening our AI models and expanding what we can design next.

Functionally optimized

Operating in stealth to overcome the limitations of today’s therapeutics

With Synteins™, we can now bring the next generation of therapies to life. Natural proteins and biologic drugs are easily neutralized by the body’s defenses. In contrast, Synteins™ are compatible with human biology, but remain extraordinarily durable by evading the body’s natural protease defenses while remaining immune-silent.

Bringing the ideal biologic to life.

Synteins™ have unlimited potential to revolutionize treatment paradigms across a broad range of therapeutic areas, including oncology, immunology, and metabolic diseases. They offer the possibility of less frequent dosing, oral delivery, and reaching tissues that were previously impossible to access and treat with biologics, such as brain, kidney, liver, heart, lung, muscle, and deep into tumors.